Nighttime heartburn in patients with gastroesophageal reflux disease under routine care

Digestion

Volumn 77, Issue 2, 2008, Pages 69-72

  Nocon, Marc ^a   Labenz, Joachim ^b   Jaspersen, Daniel ^c   Leodolter, Andreas ^b   Meyer Sabellek, Wolfgang ^d,g   Stolte, Manfred ^e   Vieth, Michael ^e   Lind, Tore ^d,g   Malfertheiner, Peter ^f   Willich, Stefan N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Ev Jung Stilling Krankenhaus   (Germany)

^c KLINIKUM FULDA   (Germany)

^d ASTRAZENECA   (United Kingdom)

^e INSTITUTE OF PATHOLOGY   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Gastroesophageal reflux disease; Nighttime heartburn; Reflux symptoms

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; LOGISTIC REGRESSION ANALYSIS; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; CIRCADIAN RHYTHM; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 42349104204     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121372     Document Type: Article

References (28)

1. Frank L, Kleinman L, Ganoczy D, et al: Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000;45:809-818.
2. Kulig M, Leodolter A, Vieth M, et al: Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - An analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-776.
3. Willich SN, Nocon M, Kulig M, et al: Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 2006;23:371-376.
4. Dent J, El-Serag HB, Wallander MA, et al: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-717.
5. Nocon M, Keil T, Willich SN: Prevalence and sociodemographics of reflux symptoms in Germany - Results from a national survey. Aliment Pharmacol Ther 2006;23:1601-1605.
6. Farup C, Kleinman L, Sloan S, et al: The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161:45-52.
7. Shaker R, Castell DO, Schoenfeld PS, et al: Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98:1487-1493.
8. Orr WC: Night-time gastro-oesophageal reflux disease: prevalence, hazards, and management. Eur J Gastroenterol Hepatol 2005;17:113-120.
9. Orr WC, Allen ML, Robinson M: The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol 1994;89:509-512.
10. DeMeester TR, Johnson LF, Joseph GJ, et al: Patterns of gastroesophageal reflux in health and disease. Ann Surg 1976;184:459-470.
11. Konermann M, Radu B, Liebetrau M, et al: Nocturnal gastroesophageal reflux as a cause of refractory chronic laryngitis - Pathophysiology and management. Wien Med Wochenschr 1999;151:142-146.
12. Harding SM: Nocturnal asthma: role of nocturnal gastroesophageal reflux. Chronobiol Int 1999;16:641-662.
13. Kulig M, Nocon M, Vieth M, et al: Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004;57:580-589.
14. Malfertheiner P, Lind T, Willich S, et al: Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005;54:746-751.
15. Lundell LR, Dent J, Bennett JR, et al: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-180.
16. Shaw MJ, Talley NJ, Beebe TJ, et al: Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-57.
17. Nocon M, Kulig M, Leodolter A, et al: Validation of the Reflux Disease Questionnaire for a German population. Eur J Gastroenterol Hepatol 2005;17:229-233.
18. Jaspersen D, Kulig M, Labenz J, et al: Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003;17:1515-1520.
19. Jaspersen D, Labenz J, Willich SN, et al: Long-term clinical course of extra-oesophageal manifestations in patients with gastrooesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis 2006;38:233-238.
20. Richter JE, Bochenek W: Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000;95:3071-3080.
21. Miner P Jr, Orr W, Filippone J, et al: Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-1339.
22. Nocon M, Labenz J, Jaspersen D, et al: Long-term treatment of patients with gastro-oesophageal reflux disease in routine care - Results from the ProGERD study. Aliment Pharmacol Ther 2007;25:715-722.
23. Hungin AP, Rubin GP, O'Flanagan H: Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451-453.
24. Orr WC: Therapeutic options in the treatment of nighttime gastroesophageal reflux. Digestion 2005;72:229-238.
25. Shimatani T, Inoue M, Kuroiwa T, et al: Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004;19:113-122.
26. Hammer J, Schmidt B: Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004;19:1105-1110.
27. Hatlebakk JG, Katz PO, Kuo B, et al: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-1240.
28. Ang TL, Fock KM: Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 2006;21(suppl 5):S125-S128.